
    
      This is a Phase 2 clinical trial. A total of 10 FRDA patients will be recruited All subjects
      will be treated with a dose of 100-150-200-micrograms of IFN gamma 1b (ImukinÂ®)
      subcutaneously, with an interval of 14 days, for a total of 3 injections.
    
  